Neuroscience R&D Newsroom

OUR COMMITMENT TO NEUROPSYCHIATRIC, NEURODEGENERATIVE DISEASES AND NEUROSCIENCE AUTOANTIBODY DISEASES

Thank you for visiting the Johnson & Johnson Neuroscience R&D Newsroom!

Below, please find our meeting news, social feeds, and more information about our progress and commitment to developing innovative medicines for neuropsychiatric, neurodegenerative diseases and neuroscience autoantibody disease, including depression, schizophrenia, Alzheimer's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and more.

OUR Leadership

Bill Martin, Ph.D.
Global Therapeutic Area Head
Neuroscience
View Bill's profile

Peter Fang
Worldwide Vice President
Neuroscience
Global Commercial Strategy Organization
View Peter's profile

Fiona Elwood, Ph.D.
Disease Area Leader
Neurodegeneration
View Fiona’s profile

Wayne Drevets, M.D.
Disease Area Leader
Neuropsychiatry
View Wayne’s profile

About NEUROSCIENCE

Johnson & Johnson is leading the precision neuroscience revolution to reduce the burden and disability caused by serious nervous system disorders. Our goal is to deliver breakthrough solutions for people with neuropsychiatric, neurodegenerative, and neurological autoantibody-driven diseases. Our strategy harnesses scientific advances in four areas: human genetics, data science, biomarkers, and digital health. We leverage these advances to enable precision approaches for target and patient identification, target modulation and therapeutic focus. Building on our nearly seven-decade legacy in psychiatry, we are committed to making an impact for the over one billion people affected by diseases of the brain.